Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...
Management anticipates top line data from the EXPLORE-OSA trial in the near future and continues to focus on pre-NDA preparations for lorundrostat, with a scheduled meeting with the FDA in Q4 2025.
CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience ...
This article provides ChatGPT prompts to improve team meetings. It emphasizes pre-meeting preparation like mental resets and body language adjustments. Prompts guide crafting strong opening and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results